A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis

被引：20

作者：

Jurczak, Wojciech ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Hess, Georg ^{[3
]}

Gaidano, Gianluca ^{[4
]}

Provencio, Mariano ^{[5
]}

Nagy, Zsolt ^{[6
]}

Robak, Tadeusz ^{[7
]}

Maddocks, Kami J. ^{[8
]}

Buske, Christian ^{[9
]}

Ambarkhane, Sumeet ^{[10
]}

Brugger, Wolfram ^{[10
]}

Dirnberger-Hertweck, Maren ^{[10
]}

Tillmanns, Sascha ^{[10
]}

Weirather, Johannes ^{[10
]}

Blum, Kristie ^{[11
]}

机构：

[1] Jagiellonian Univ Med Coll, Dept Hematol, Krakow, Poland

[2] Univ Bologna, Ist Ematol, Bologna, Italy

[3] Johannes Gutenberg Univ Mainz, Dept Hematol Med Oncol & Pneumol, Mainz, Germany

[4] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[5] Univ Autonoma Madrid, Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain

[6] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[7] Med Univ Lodz, Dept Hematol, Lodz, Poland

[8] Ohio State Univ, Dept Internal Med, Arthur G James Comprehens Canc Ctr, Wexner Med Ctr, Columbus, OH 43210 USA

[9] Comprehens Canc Ctr Ulm, Inst Expt Canc Res, Ulm, Germany

[10] MorphoSys AG, Planegg, Germany

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124297

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4078

引用

页数：4

共 50 条

[1] A PHASE IIA STUDY OF SINGLE- AGENT MOR208, AN FC-OPTIMIZED ANTI-CD19 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
Jurczak, W.
Zinzani, P. L.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Korolkiewicz, R.
Winderlich, M.
Blum, K.
HAEMATOLOGICA, 2015, 100 : 395 - 396
[2] A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Blum, Kristie A.
Maddocks, Kami
Nagy, Zsolt
Zinzani, Pier Luigi
Goy, Andre
Provencio, Mariano
Robak, Tadeusz
Buske, Christian
Korolkiewicz, Roman Pawel
Winderlich, Mark
Jurczak, Wojciech
BLOOD, 2014, 124 (21)
[3] Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Korolkiewicz, Roman Pawel
Striebel, Frank
Blum, Kristie
BLOOD, 2015, 126 (23)
[4] Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Korolkiewicz, Roman
Winderlich, Mark
Blum, Kristie A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Dirnberger-Hertweck, M.
Korolkiewicz, R.
Blum, K. A.
ANNALS OF ONCOLOGY, 2018, 29 (05) : 1266 - 1272
[6] SUBGROUP ANALYSES OF DIFFUSE LARGE B-CELL LYMPHOMA AND INDOLENT LYMPHOMA COHORTS FROM A PHASE IIA STUDY OF SINGLE-AGENT MOR208 IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Buske, C.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K.
HAEMATOLOGICA, 2016, 101 : 317 - 317
[7] Subgroup analyses of diffuse large B-cell lymphoma and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL)
Buske, C.
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K. A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 72 - 72
[8] Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Ambarkhane, Sumeet
Winderlich, Mark
Dirnberger-Hertweck, Maren
Endell, Jan
Blum, Kristie A.
BLOOD, 2016, 128 (22)
[9] Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study
Ben Barouch, Sharon
Bhella, Sita
Kridel, Robert
Kukreti, Vishel
Prica, Anca
Crump, Michel
Kuruvilla, John
LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1879 - 1886
[10] Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase Ha study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kamij.
Buske, Christian
Ambarkhane, Sumeet Vijay
Winderlich, Mark
Endell, Jan
Blum, Kristie A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →